Companies › Kolon TissueGene
1 active drug program in 1 registered trial: 1 Phase 3; Immunology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TG-C (TissueGene-C) Non-transduced human chondrocytes combined with irradiated transduced human GP2-293 cells | TGFB1 | Phase 3 | Degenerative Osteoarthritis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03203330 | TG-C (TissueGene-C) | Phase 3 | Degenerative Osteoarthritis | Immunology | Jul 2024 |
Bristol-Myers Squibb Sirnaomics FBD Biologics Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Bicara Therapeutics
ALK-Abelló Doron Therapeutics UnicoCell Biomed medac Abeona Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.